Physician profile
Shoaib Ali
NPI 1124236211
$1,885.51
in general payments reported to CMS, 2019-2025
23 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $70.14 · 2021: $332 · 2022: $358 · 2023: $389 · 2024: $301 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $820 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $819.63 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $241.70 | 2019-2025 | Veltassa, Korsuva |
| Akebia Therapeutics INC | $217.64 | 2019-2024 | Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $201.09 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $179.68 | 2019-2024 | Farxiga |
| Aurinia Pharma U.S., INC. | $175.39 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $124.43 | 2019-2025 | Rayaldee |
| Horizon Therapeutics Plc | $124.26 | 2022-2023 | Krystexxa |
| Nxstage Medical, INC. | $96.85 | 2022-2023 | Nxstage System One, Liberty Select Cycler |
| Amgen INC. | $93.43 | 2019-2024 | Tavneos |
| Mallinckrodt Enterprises LLC | $88.12 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $65.02 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $56.75 | 2020-2025 | Terlivaz |
| Calliditas Therapeutics US INC. | $49.08 | 2022-2024 | Tarpeyo |
| Fresenius USA Marketing, INC. | $33.18 | 2019-2023 | Velphoro, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.55 | 2025 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $19.30 | 2019 | |
| Ardelyx, INC. | $16.02 | 2024 | Ibsrela |
| Glaxosmithkline, LLC. | $15.23 | 2023 | Benlysta |
| Novartis Pharmaceuticals Corporation | $14.43 | 2025 | |
| Travere Therapeutics, INC. | $14.38 | 2025 | |
| Shire North American Group INC | $14.35 | 2019 | |
| Ani Pharmaceuticals, INC. | $13.86 | 2024 | Purified Cortrophin Gel |
| Janssen Pharmaceuticals, INC | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shoaib Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.